Basic haematologic parameters and serum gamma-glutamyl-transferase (GGT) activity were evaluated in a five-year prospective follow-up study of 25 patients with newly diagnosed epilepsy starting treatment with carbamazepine. In addition, we evaluated the effects of replacing carbamazepine by oxcarbazepine on these parameters, erythrocyte folate concentrations and serum vitamin B i2 levels in 12 male patients with epilepsy.
INTRODUCTION
The use of carbamazepine, a first-line antiepileptic drug in most cases of adult-onset epilepsy, is associated with haematologic changes including mild leukopenia, decreased red blood cell count and blood haemoglobin concentrations, and enlargement of the red blood cells without anaemia'-'.
However, severe hematologic sideeffects such as aplastic anaemia and agranulocytosis are rare5v8.
The life-threatening haematologic side-effects of carbamazepine are caused by allergic or toxic mechanisms*, but the mechanisms of carbamazepine-induced leukopenia and macrocytosis are unknown. Folate deficiency has been described in association with the use of many anticonvulsant drugs with liver enzyme inducing properties l"-i4. Folate is necessary for the normal maturation of both red and white blood cells15S'6, and, therefore, it seems possible that liver enzyme induction and the resulting folate deficiency could be responsible for the haematologic changes during carbamazepine medication.
Oxcarbazepine, a keto-derivative of carbamazepine, is a novel anticonvulsant drug which structurally closely resembles carbamazepine. The two drugs appear to have comparable anticonvulsant efficacy, and oxcarbazepine seems to be at least as well tolerated as carbamazepine'7Y'8.
However, oxcarbazepine does not have the liver enzyme inducing properties of carbamazepine'g*20.
In this study we first evaluated basic haematologic parameters and liver enzyme induction during the first 5 years of carbamazepine medica-tion in patients with newly diagnosed epilepsy. Thereafter, the changes in haematologic indices, folate concentrations in erythrocytes, serum vitamin B,* levels, and serum gamma-glutamyltransferase (GGT) activity were measured in male patients with epilepsy after replacing carbamazepine with oxcarbazepine.
PATIENTS AND METHODS
The study was carried out at the Outpatient Department of Neurology in the University Hospital of Oulu with the approval of the Ethics committee of the Medical Faculty of the University of Oulu. The principles of the Declaration of Helsinki were followed. Informed consent was obtained from all patients. The type of epilepsy was classified according to the International League Against Epilepsy (ILAE) classification*'.
Patients beginning carbamazepine treatment
Altogether 25 consecutive patients with recently diagnosed idiopathic/cryptogenic epilepsy without prior medication participated in the study after giving their informed consent. They had all suffered at least two partial or tonic-clonic seizures during the previous year before the medication was started. The use of any other regular medication, alcohol abuse, pregnancy, lactation, or any disease possibly interfering with the evaluation of haematologic or liver enzyme parameters were regarded as exclusion criteria. There were 12 female patients with a mean (&sd) age of 35.7 f 14.4 years, and 13 male patients with a mean (&sd) age of 30.7 f 13.3 years at the beginning of the study. Fourteen patients suffered from generalized epilepsy, and 11 patients from localization related epilepsy. The seizure control was good in most cases after carbamazepine medication had been set at the therapeutic serum level.
The mean carbamazepine dose was 525 f 79mg and the mean serum carbamazepine concentration was 27.4 f 6.1 pmol/l after 2 months medication, 517 f 87 mg and 26.3 f 5.4 pmol/l after 1 year, and 568 f 187 mg and 26.5 f 6.0 pmol/l after 5 years, respectively.
The patients were studied before medication, and 2 months, 1 year, and 5 years after carbamazepine was started. After clinical examination blood samples were drawn for the evaluation of haematologic parameters and gamma-glutamyl-transferase (GGT) activity at 8.30 a.m. after an overnight fast.
Patients changing from carbamazepine to oxcarbazepine Twelve randomly-selected male patients with epilepsy visiting the Outpatient Department of Neurology participated in this part of the study. The mean age of these patients was 29 years (range, 21-40 years). Eleven patients suffered from idiopathic/cryptogenic epilepsy and one from symptomatic epilepsy after a CNS infection in infancy. Six patients had generalized epilepsy, and six patients had localization related epilepsy. All patients were initially receiving carbamazepine monotherapy. The daily dose of the medication has been unaltered for at least 1 year before the study. The mean duration of carbamazepine medication was 8.9 years (range, 3.5-15 years), the mean daily dose of carbamazepine was 571 f 136 mg, and the mean serum concentration was 25.7 f 6.2 gmol/l. The seizure control was good in all cases during carbamazepine medication: 7 patients were completely seizure free, and 5 experienced a few annual seizures despite the medication. None of the patients showed any symptoms or signs of diseases other than epilepsy, and none used any regular medication other than carbamazepine.
The mean daily oxcarbazepine dose was 913 f 251 mg and the mean serum concentration of 10, 11-dihydro-lo-hydroxy-carbamazepine, the main active metabolite of oxcarbazepine, was 35.9 f 8.7 kmol/l after 2 months' oxcarbazepine medication, and lOOOk 322mg and 43.1 f 12.9 pmol/l after 6 months' medication, respectively.
The patients were studied three times. At the first visit they were on carbamazepine medication. After the blood samples had been taken, carbamazepine medication was replaced by an equivalent daily dose of oxcarbazepine, i.e. the daily oxcarbazepine dose was 1.5-fold compared with the daily dose of carbamazepine".
If the patients experienced seizures during oxcarbazepine medication, the dose was increased. The second and third examinations were made 2 and 6 months after the switch from carbamazepine to oxcarbazepine.
During every visit a clinical examination was done, and thereafter blood samples were obtained for the measurement of the haematologic parameters, serum GGT activity, and the erythrocyte folate and serum vitamin B,, concentrations at 8.30 a.m. after an overnight fast. 
Assays
The basic haematologic laboratory parameters (white blood cell count, WBC; red blood cell count, RBC, erythrocyte volume = mean corpuscular volume, MCV; haemoglobin concentration and haematocrit)
were
System (ACS) (Ciba Corning Corp., Medfield, Ma.). The analyses were performed according to the instructions of the manufacturer.
Statistics
The statistical analysis of the results was performed using analysis of variance (ANOVA) for repeated measures and Fisher's lsd test.
RESULTS
The results are presented in Tables 1 and 2 . The mean WBC decreased after 2 months' carbamazepine treatment and remained at this lower level during the first 5 years of medication (Table  1) . Furthermore, a slight decrease was found in the mean red blood cell count (RBC) after 2 months carbamazepine treatment and thereafter. The decrease in mean blood haemoglobin concentration was transient during the first 12 months of carbamazepine medication. The MCV increased gradually and progressively during the years of carbamazepine treatment, and the increase was statistically significant after 5 years (P <O.OOl). A progressive increase of serum GGT activities was also found during the first 5 years of carbamazepine medication.
The mean WBC increased 2 months after replacing carbamazepine by oxcarbazepine and it was still higher after 6 months ( Table 2) . The MCV decreased, but the mean RBC, haemoglobin concentration, and the haematocrit remained unaltered after the medication was changed. Serum GGT activities decreased, and the erythrocyte folate levels increased after 2 months and showed a further increase after 6 months oxcarbazepine medication.
The concentrations of serum vitamin B,2 increased after 6 months.
DISCUSSION
The mean WBC decreased after 2 months' carbamazepine medication, and remained at this lower level quite constantly during the next 5 years. The MCV and serum GGT activities increased progressively during the 5 years. Replacing carbamazepine by oxcarbazepine resuited' in a decrease in serum GGT activities indicating a normalization of liver enzyme induction. Furthermore, a concomitant increase in erythrocyte folate levels and serum vitamin B,2 concentrations was observed, and the WBC increased and the MCV decreased after the change in the medication.
The decreased mean WBC, the slight transient decrease of serum haemoglobin, as well as the decreased RBC during carbamazepine medication are in accordance with the previous literature1'3*"*6-8.24. The progressive increase of the size of the erythrocytes during the first 5 years of carbamazepine medication has not been reported earlier, although an increase after 2 years was GGT, gamma-glutamyl-transferase *P < 0.05, **P < 0.01, ***P < 0.001; ANOVA for repeated measures and Fisher's Isd test, compared with the values before medication.
J.I.T. lsojatvi et a/ Table 1 . *P < 0.05, **P < 0.01, ***P < 0.001; ANOVA for repeated measures and Fisher's Isd test, compared with the values during carbamazepine medication.
foundg. The changes in serum GGT activities, erythrocyte folate and serum vitamin B12 levels, and haematologic parameters after replacing carbamazepine with oxcarbazepine are new findings.
Serum GGT activities increased progressively during the 5 years of carbamazepine medication and this phenomenon is probably associated with liver enzyme induction caused by carbamazepine23. On the other hand serum GGT activities decreased after substituting oxcarbazepine for carbamazepine indicating a normalization of liver enzyme induction. Furthermore, it has also been shown previously by measuring antipyrine kinetics that the induction of the liver P450 enzyme system is normalized after changing the medication from carbamazepine to oxcarbazepine". Folate deficiency has been described in association with the use of many anticonvulsant drugs with liver enzyme inducing properties'&", although the decrease was not statistically significant in a short-term prospective study during carbamazepine medication25. It has been suggested that the enzymes involved in folate metabolism may be induced or the demand for folic acid as a coenzyme in drug-induced enzyme reactions may be increased during the use of liver enzyme inducing antiepileptic drugs137'4. Folate is necessary for the normal maturation of both red and white blood cells, and folate deficiency can lead to macrocytosis of the red blood cells, and to leukopeniai5v16. Therefore, folate deficiency could lead to maturation defects in red and white blood cells and to the development of macrocytosis and leukopenia during carbamazepine treatment. In the present study folate concentrations were not analysed in the patients starting treatment with carbamazepine, but the concomitant increase in erythrocyte folate levels with the increase in the WBC and decrease in the size of the erythrocytes after replacing carbamazepine with oxcarbazepine supports this hypothesis. It is also possible that vitamin Bi2 has some role in these changes. The decreased concentrations of serum vitamin Bi2 could contribute to the decrease in folate concentrations together with the direct effects of the medication on folate metabolism via liver enzyme induction.
The increased size of the erythrocytes was not associated with anaemia during carbamazepine medication, and, therefore, did not indicate a clinically significant disturbance of erythrocyte maturation. However, it seems that the underlying difference between the metabolic effects of carbamazepine and oxcarbazepine may be more important than the resulting mild haematologic changes. The different effects of carbamazepine and oxcarbazepine on folate metabolism could have certain clinical implications.
It has been reported that the occurrence of developmental abnormalities in the infants of epileptic mothers can be associated with low serum folate levels during pregnancy2'j, and, therefore, the use of oxcarbazepine instead of carbamazepine may be preferred in young women with epilepsy.
In conclusion, the results of the present study show that the mild changes in haematologic indices during carbamazepine medication are normalized after replacing carbamazepine with oxcarbazepine.
The underlying mechanism is probably the concomitant increase in erythrocyte folate levels and serum vitamin Bi2 concentrations, which results from the normalization of liver P450 enzyme system induction.
